Stockscreener 앱 받기
0.00
100.00%
-2.05
Aadi Bioscience Inc 주식(AADI)의 최신 뉴스
Reviewing Aadi Bioscience (NASDAQ:AADI) & UCB (OTCMKTS:UCBJF) - Defense World
Whitehawk Therapeutics Reports Strong Q1 2025 Results - TipRanks
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights - PR Newswire
Geode Capital Management LLC Purchases 8,546 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience (NASDAQ:AADI) Trading Down 0.6% – Should You Sell? - Defense World
Ten March deals passed $1B, totaling $25.31B in value - BioWorld MedTech
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Analyzing Aadi Bioscience (NASDAQ:AADI) and Orgenesis (NASDAQ:ORGS) - Defense World
Whitehawk Therapeutics - The Pharma Letter
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations - MarketScreener
Aadi Bioscience to Participate at Upcoming Investor Conferences - MarketScreener
Aadi Bioscience to Participate in Upcoming Investor Events - MarketScreener
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - MarketScreener
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting - MarketScreener
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference - MarketScreener
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes - MarketScreener
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M - MarketScreener
Aadi Bioscience, (AADI) reports earnings - Quartz
Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz
Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com Australia
Whitehawk Therapeutics sells subsidiary for $102.4 million By Investing.com - Investing.com Canada
Whitehawk sells Aadi Subsidiary to Kaken for $100 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million By Investing.com - Investing.com India
Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals - Marketscreener.com
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - The Victoria Advocate
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - MarketScreener
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences - MarketScreener
Aadi Bioscience Announces Leadership Transition - MarketScreener
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - MarketScreener
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline - TipRanks
Suvretta Capital Management, LLC Acquires Significant Stake in A - GuruFocus
Aadi Bioscience Announces Approval of All Proposals at Special M - GuruFocus.com
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - MarketScreener
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - Marketscreener.com
HC Wainwright Adjusts Price Target on Aadi Bioscience to $45 From $48, Maintains Buy Rating - MarketScreener
Aadi Bioscience, Inc. Announces CEO Changes - MarketScreener
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - Marketscreener.com
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - MarketScreener
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Marketscreener.com
Aadi Bioscience Inc (AADI) Q4 2024 Earnings Call Highlights: Strategic Transition and Financial ... By GuruFocus - Investing.com Canada
Whitehawk Therapeutics: Strategic Shift and Financial Outlook - TipRanks
Aadi rebrands as Whitehawk Therapeutics in new ADC focus - The Pharma Letter
Aadi Bioscience, Inc. will Change its Name to Whitehawk Therapeutics, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
Aadi Bioscience earnings missed by $0.46, revenue fell short of estimates - Investing.com UK
Aadi Bioscience Inc changes name to Whitehawk Therapeutics -March 18, 2025 at 05:58 pm EDT - Marketscreener.com
Aadi Bioscience Inc changes name to Whitehawk Therapeutics - TradingView
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company - PR Newswire
Major Transformation: Aadi Becomes Whitehawk with $180M War Chest for ADC Cancer Programs - Stock Titan
AADI BIOSCIENCE Earnings Preview: Recent $AADI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update - BioSpace
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Resu - GuruFocus.com
17.27%
1.06%
자본화:
|
볼륨(24시간):